Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review

Hanna Fjeldheim Dale, Stella Hellgren Rasmussen, Özgün Ömer Asiller, Gülen Arslan Lied, Hanna Fjeldheim Dale, Stella Hellgren Rasmussen, Özgün Ömer Asiller, Gülen Arslan Lied

Abstract

Irritable bowel syndrome (IBS) is a frequent functional gastrointestinal disorder, and alterations in the gut microbiota composition contributes to symptom generation. The exact mechanisms of probiotics in the human body are not fully understood, but probiotic supplements are thought to improve IBS symptoms through manipulation of the gut microbiota. The aim of this systematic review was to assess the latest randomized controlled trials (RCTs) evaluating the effect of probiotic supplementation on symptoms in IBS patients. A literature search was conducted in Medline (PubMed) until March 2019. RCTs published within the last five years evaluating effects of probiotic supplements on IBS symptoms were eligible. The search identified in total 35 studies, of which 11 met the inclusion criteria and were included in the systematic review. Seven studies (63.6%) reported that supplementation with probiotics in IBS patients significantly improved symptoms compared to placebo, whereas the remaining four studies (36.4%) did not report any significant improvement in symptoms after probiotic supplementation. Of note, three studies evaluated the effect of a mono-strain supplement, whereas the remaining eight trials used a multi-strain probiotic. Overall, the beneficial effects were more distinct in the trials using multi-strain supplements with an intervention of 8 weeks or more, suggesting that multi-strain probiotics supplemented over a period of time have the potential to improve IBS symptoms.

Keywords: gut microbiota; irritable bowel syndrome; probiotics.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram depicting the literature search in PubMed (Medline) for this systematic literature.

References

    1. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712–721. doi: 10.1016/j.cgh.2012.02.029.
    1. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393–1407. doi: 10.1053/j.gastro.2016.02.031.
    1. Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S., Vergnolle N., Zoetendal E.G. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305–1318. doi: 10.1053/j.gastro.2016.02.028.
    1. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. doi: 10.1053/j.gastro.2005.11.061.
    1. Marsh A., Eslick E.M., Eslick G.D. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur. J. Nutr. 2016;55:897–906. doi: 10.1007/s00394-015-0922-1.
    1. Lea R., Whorwell P.J. New insights into the psychosocial aspects of irritable bowel syndrome. Curr. Gastroenterol. Rep. 2003;5:343–350. doi: 10.1007/s11894-003-0073-z.
    1. Holtmann G.J., Ford A.C., Talley N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133–146. doi: 10.1016/S2468-1253(16)30023-1.
    1. Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445–450. doi: 10.1053/j.gastro.2006.05.053.
    1. Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., Singh S., Grover M. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology. 2017;152:1042–1054. doi: 10.1053/j.gastro.2016.12.039.
    1. Lin H.C. Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome. Jama. 2004;292:852–858. doi: 10.1001/jama.292.7.852.
    1. Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010;22:512–519. doi: 10.1111/j.1365-2982.2009.01427.x.
    1. Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887–2892. doi: 10.3748/wjg.15.2887.
    1. Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33. doi: 10.1053/j.gastro.2007.04.005.
    1. Durban A., Abellan J.J., Jimenez-Hernandez N., Artacho A., Garrigues V., Ortiz V., Ponce J., Latorre A., Moya A. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol. Ecol. 2013;86:581–589. doi: 10.1111/1574-6941.12184.
    1. Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–123. doi: 10.1053/j.gastro.2016.09.049.
    1. Malinen E., Krogius-Kurikka L., Lyra A., Nikkila J., Jaaskelainen A., Rinttila T., Vilpponen-Salmela T., von Wright A.J., Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J. Gastroenterol. 2010;16:4532–4540. doi: 10.3748/wjg.v16.i36.4532.
    1. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506–514. doi: 10.1038/nrgastro.2014.66.
    1. Brown A.C., Valiere A. Probiotics and medical nutrition therapy. Nutr. Clin. Care. 2004;7:56–68.
    1. Wilkins T., Sequoia J. Probiotics for gastrointestinal conditions: A summary of the evidence. Am. Fam. Phys. 2017;96:170–178.
    1. Ritchie M.L., Romanuk T.N. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE. 2012;7:e34938. doi: 10.1371/journal.pone.0034938.
    1. Cremon C., Barbaro M.R., Ventura M., Barbara G. Pre-and probiotic overview. Curr. Opin. Pharmacol. 2018;43:87–92. doi: 10.1016/j.coph.2018.08.010.
    1. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007;13:35–37. doi: 10.1038/nm1521.
    1. Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182–190. doi: 10.1136/gut.2005.066100.
    1. Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580–591. doi: 10.1053/gast.2001.27224.
    1. O’Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O’Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551. doi: 10.1053/j.gastro.2004.11.050.
    1. Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:e13513. doi: 10.1111/nmo.13513.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009;151:264–269. doi: 10.7326/0003-4819-151-4-200908180-00135.
    1. Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennila J., Tarpila A., Lahtinen S., Ouwehand A.C., Veijola L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J. Gastroenterol. 2016;22:10631–10642. doi: 10.3748/wjg.v22.i48.10631.
    1. Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., Majeed S., Karri S.K. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: A double blind randomized placebo controlled pilot clinical study. Nutr. J. 2016;15:21. doi: 10.1186/s12937-016-0140-6.
    1. Pineton de Chambrun G., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis. 2015;47:119–124. doi: 10.1016/j.dld.2014.11.007.
    1. Hod K., Sperber A.D., Ron Y., Boaz M., Dickman R., Berliner S., Halpern Z., Maharshak N., Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol. Motil. 2017;29:e13037. doi: 10.1111/nmo.13037.
    1. Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult(R)) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18:71. doi: 10.1186/s12876-018-0788-9.
    1. Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch. Iran. Med. 2014;17:466–470.
    1. Ludidi S., Jonkers D.M., Koning C.J., Kruimel J.W., Mulder L., van der Vaart I.B., Conchillo J.M., Masclee A.A. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol. Motil. 2014;26:705–714. doi: 10.1111/nmo.12320.
    1. Mezzasalma V., Manfrini E., Ferri E., Sandionigi A., La Ferla B., Schiano I., Michelotti A., Nobile V., Labra M., Di Gennaro P. A randomized, double-blind, placebo-controlled trial: The efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. Biomed. Res. Int. 2016;2016:4740907. doi: 10.1155/2016/4740907.
    1. Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–A 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51–62. doi: 10.1111/apt.12787.
    1. Staudacher H.M., Lomer M.C.E., Farquharson F.M., Louis P., Fava F., Franciosi E., Scholz M., Tuohy K.M., Lindsay J.O., Irving P.M., et al. A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: A randomized controlled trial. Gastroenterology. 2017;153:936–947. doi: 10.1053/j.gastro.2017.06.010.
    1. Wong R.K., Yang C., Song G.H., Wong J., Ho K.Y. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: A randomized double-blinded placebo study. Dig. Dis. Sci. 2015;60:186–194.
    1. Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044–1060. doi: 10.1111/apt.15001.
    1. Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:1547–1561. doi: 10.1038/ajg.2014.202.
    1. Hungin A.P.S., Mitchell C.R., Whorwell P., Mulligan C., Cole O., Agreus L., Fracasso P., Lionis C., Mendive J., Philippart de Foy J.M., et al. Systematic review: Probiotics in the management of lower gastrointestinal symptoms—An updated evidence-based international consensus. Aliment. Pharmacol. Ther. 2018;47:1054–1070. doi: 10.1111/apt.14539.
    1. Balsari A., Ceccarelli A., Dubini F., Fesce E., Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185–194.
    1. Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792–1801. doi: 10.1053/j.gastro.2011.07.043.
    1. Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395–402. doi: 10.1046/j.1365-2036.1997.142318000.x.
    1. Eswaran S.L., Chey W.D., Han-Markey T., Ball S., Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am. J. Gastroenterol. 2016;111:1824–1832. doi: 10.1038/ajg.2016.434.
    1. Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Quigley E.M. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am. J. Gastroenterol. 2014;109 doi: 10.1038/ajg.2014.187.
    1. Camilleri M., Mayer E.A., Drossman D.A., Heath A., Dukes G.E., McSorley D., Kong S., Mangel A.W., Northcutt A.R. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol. Ther. 1999;13:1149–1159. doi: 10.1046/j.1365-2036.1999.00610.x.
    1. O’Toole P.W., Marchesi J.R., Hill C. Next-generation probiotics: The spectrum from probiotics to live biotherapeutics. Nat. Microbiol. 2017;2:17057. doi: 10.1038/nmicrobiol.2017.57.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj